These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 16170757)

  • 1. A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy.
    Collier AC; Ribaudo H; Mukherjee AL; Feinberg J; Fischl MA; Chesney M;
    J Infect Dis; 2005 Oct; 192(8):1398-406. PubMed ID: 16170757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors.
    Maggiolo F; Ravasio L; Ripamonti D; Gregis G; Quinzan G; Arici C; Airoldi M; Suter F
    Clin Infect Dis; 2005 Jan; 40(1):158-63. PubMed ID: 15614706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of an adherence clinic on behavioral outcomes and virologic response in treatment of HIV infection: a prospective, randomized, controlled pilot study.
    Rathbun RC; Farmer KC; Stephens JR; Lockhart SM
    Clin Ther; 2005 Feb; 27(2):199-209. PubMed ID: 15811483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of directly administered antiretroviral therapy and adherence case management intervention.
    Wohl AR; Garland WH; Valencia R; Squires K; Witt MD; Kovacs A; Larsen R; Hader S; Anthony MN; Weidle PJ
    Clin Infect Dis; 2006 Jun; 42(11):1619-27. PubMed ID: 16652320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
    Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
    AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic.
    McNabb J; Ross JW; Abriola K; Turley C; Nightingale CH; Nicolau DP
    Clin Infect Dis; 2001 Sep; 33(5):700-5. PubMed ID: 11486292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of short-term success of antiretroviral therapy in HIV infection.
    Oette M; Kroidl A; Göbels K; Stabbert A; Menge M; Sagir A; Kuschak D; O'hanley T; Bode JG; Häussinger D
    J Antimicrob Chemother; 2006 Jul; 58(1):147-53. PubMed ID: 16687458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
    Moore DM; Hogg RS; Yip B; Wood E; Harris M; Montaner JS
    HIV Med; 2006 Jul; 7(5):311-6. PubMed ID: 16945076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.
    Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC
    Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of an intervention to prevent adherence failure among HIV-infected patients initiating antiretroviral therapy.
    Koenig LJ; Pals SL; Bush T; Pratt Palmore M; Stratford D; Ellerbrock TV
    Health Psychol; 2008 Mar; 27(2):159-69. PubMed ID: 18377134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India.
    Shah B; Walshe L; Saple DG; Mehta SH; Ramnani JP; Kharkar RD; Bollinger RC; Gupta A
    Clin Infect Dis; 2007 May; 44(9):1235-44. PubMed ID: 17407045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART.
    Castor D; Vlahov D; Hoover DR; Berkman A; Wu YF; Zeller B; Brechtl J; Hammer SM
    J Med Virol; 2009 Aug; 81(8):1323-35. PubMed ID: 19551816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART.
    Collazos J; Asensi V; Cartón JA
    AIDS; 2007 Apr; 21(7):835-43. PubMed ID: 17415038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia.
    Podsadecki TJ; Vrijens BC; Tousset EP; Rode RA; Hanna GJ
    J Infect Dis; 2007 Dec; 196(12):1773-8. PubMed ID: 18190257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
    J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
    Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
    Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of adherence to highly active antiretroviral therapy among HIV-1-infected patients in Côte d'Ivoire.
    Diabaté S; Alary M; Koffi CK
    AIDS; 2007 Aug; 21(13):1799-803. PubMed ID: 17690579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
    Gandhi T; Nagappan V; Cinti S; Wei W; Kazanjian P
    Clin Infect Dis; 2007 Oct; 45(8):1085-92. PubMed ID: 17879930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 100% adherence study: educational workshops vs. video sessions to improve adherence among ART-naïve patients in Salvador, Brazil.
    Sampaio-Sa M; Page-Shafer K; Bangsberg DR; Evans J; Dourado Mde L; Teixeira C; Netto EM; Brites C
    AIDS Behav; 2008 Jul; 12(4 Suppl):S54-62. PubMed ID: 18512141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.